MORGAN STANLEY PLC/CALL/ABBVIE/230/0.1/20.12.24 Stock

Warrant

DE000MB0XZ18

Market Closed - Börse Stuttgart 14:33:49 2024-06-21 EDT
0.082 EUR -9.89% Intraday chart for MORGAN STANLEY PLC/CALL/ABBVIE/230/0.1/20.12.24
Current month+67.35%
1 month+78.26%
Date Price Change
24-06-21 0.082 -9.89%
24-06-20 0.091 +19.74%
24-06-19 0.076 -13.64%
24-06-18 0.088 +25.71%
24-06-17 0.07 +1.45%

Delayed Quote Börse Stuttgart

Last update June 21, 2024 at 02:33 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ABBVIE INC.
Issuer Morgan Stanley
WKN MB0XZ1
ISINDE000MB0XZ18
Date issued 2022-11-23
Strike 230 $
Maturity 2024-12-20 (180 Days)
Parity 10 : 1
Emission price 0.63
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 0.77
Lowest since issue 0.03
Delta0.07x
Omega 13.00
Premium35.52x
Gearing185.27x
Moneyness 0.7408
Difference Strike 59.61 $
Difference Strike %+25.92%
Spread 0.008
Spread %8.89%
Theoretical value 0.0860
Implied Volatility 26.38 %
Total Loss Probability 95.08 %
Intrinsic value 0.000000
Present value 0.0860
Break even 230.92 €
Theta-0.01x
Vega0.02x
Rho0.01x

Company Profile

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
-
More about the company

Ratings for AbbVie Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: AbbVie Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
170.4 USD
Average target price
183.2 USD
Spread / Average Target
+7.54%
Consensus